Lumexa Imaging Holdings Inc Dossier - Source-backed chat

Lumexa Imaging Holdings Inc

LMRINASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.10Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $970.4M

Enterprise Value $1.7B

Shares Outstanding 96.1M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) is a leading national provider of outpatient diagnostic imaging services, operating the second-largest outpatient footprint in the United States. The company is uniquely positioned to benefit from strong secular tailwinds, including the ongoing migration of clinical care from high-cost hospital outpatient departments (HOPDs) to lower-cost outpatient centers, growing demand for advanced diagnostics driven by an aging population, and a highly fragmented provider landscape. Following its December 2025 IPO, Lumexa successfully reduced its leverage by two turns, freeing up over $50 million in annual cash flow to reinvest in high-return de novo centers and strategic joint ventures with leading health systems. Despite near-term headwinds from weather disruptions and labor inflation, Lumexa's return to profitability in Q1 2026 and its robust pipeline of advanced imaging modalities (such as PET and MRI) support a compelling growth and margin expansion story.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$9.00

Mean target$17.00

High · most bullish analyst$23.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$9.00

Government and commercial payors aggressively constrain reimbursement rates, while labor costs for specialized clinical staff continue to rise. De novo center ramp-ups face delays, and integration of joint ventures underperforms expectations. High interest rates on remaining debt and restrictive covenants limit financial flexibility, keeping the stock range-bound near its support levels.

Base CaseCentral scenario

$17.00

Matches the consensus mean

Lumexa successfully executes on its 2026 guidance, delivering consolidated revenues of $1.045 billion to $1.097 billion and Adjusted EBITDA of $234 million to $242 million. The company opens 8 to 10 de novo centers and integrates tuck-in acquisitions. Same-center advanced volume growth stabilizes in the mid-single digits, and the company achieves its projected Adjusted EPS of $0.71 to $0.77.

Bull CaseUpside scenario

$23.00

Accelerated de novo expansion and joint venture partnerships (such as the new JV with UPMC) drive market share gains. Rapid adoption of AI-enabled workflow tools significantly boosts radiologist productivity, offsetting labor cost pressures and expanding Adjusted EBITDA margins beyond the current 20-24% range. Advanced modality mix continues to shift toward high-value PET and MRI scans, driving higher average reimbursement rates.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-largest outpatient imaging footprint in the U.S. with 185+ centers across 13 states, providing significant scale and brand recognition.
Strong secular tailwinds from site-of-care migration, as outpatient imaging is approximately 60% less expensive than hospital-based services.
Substantial balance sheet improvement post-IPO, reducing leverage from 5.5x to 3.5x and generating over $50 million in annual cash savings.
High-growth advanced imaging modalities (PET scans grew 23.1% YoY in Q1 2026) driving favorable mix shift and margin expansion.

Key Investment Risks

Labor cost inflation for radiologists and technologists outpacing reimbursement rate updates from payors.
Operational vulnerability to seasonal weather disruptions, which impacted Q1 2026 Adjusted EBITDA by approximately $4 million.
High board and management turnover, representing execution risk for a newly public company.
Reliance on joint venture partnerships with health systems, which may introduce complex governance and profit-sharing dynamics.

Thesis Invalidation Triggers

A material downward revision of full-year 2026 revenue or Adjusted EBITDA guidance.
Failure to open the targeted 8 to 10 de novo centers in 2026.
A significant cybersecurity incident or data breach at a key vendor that materially impacts operations or patient trust.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.